Impact of chronic kidney disease on platelet P2Y₁₂ receptor signalling in patients with type 2 diabetes mellitus

Supplementary Material to this article is available online at www.thrombosis-online.com.

^* * Equally contributed as first authors.

• References

• 1 Haffner SM, Lehto S, Rönnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
• 2 Best PJ, Lennon R, Ting HH. et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119.
• 3 Franchi F, Angiolillo DJ, Ghukasyan T. et al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Eur Heart J 2016; 37: 1224. (Abstract)
• 4 Rollini F, Franchi F, Muñiz-Lozano A, Angiolillo DJ. Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res 2013; 06: 329-345.
• 5 Franchi F, Rollini F, Angiolillo DJ. Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2015; 08: e002760.
• 6 Fan W, Plent S, Prats J, Deliargyris EN. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol 2016; 117: 1439-1443.
• 7 Angiolillo DJ, Jakubowski JA, Ferreiro JL. et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 2014; 64: 1005-1014.
• 8 Angiolillo DJ, Bernardo E, Capodanno D. et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146.
• 9 Baber U, Bander J, Karajgikar R. et al. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost 2013; 110: 118-123.
• 10 Tello-Montoliu A, Ferreiro JL, Kodali MK. et al. Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. J Thromb Thrombolysis 2013; 36: 14-17.
• 11 Mangiacapra F, Cavallari I, Barbato E. et al. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. Am J Cardiol 2014; 113: 1124-1129.
• 12 Baber U, Mehran R, Kirtane AJ. et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry. Circ Cardiovasc Interv 2015; 08: e001683.
• 13 American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 (Suppl. 01) S13-S22.
• 14 Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation 2012; 125: 2649-2661.
• 15 Morel O, Muller C, Jesel L. et al. Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrol Dial Transplant 2013; 28: 1994-2002.
• 16 Jankowski V, Günthner T, Herget-Rosenthal S. et al. Dinucleoside polyphosphates and uremia. Semin Dial 2009; 22: 396-399.
• 17 Chang H, Yanachkov IB, Michelson AD. et al. Agonist and antagonist effects of diadenosine tet-raphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2×1 receptors. Thromb Res 2010; 125: 159-165.